Further reports from XVI International AIDS Conference, 13-18 August 2006, Toronto, Canada
7 October 2006. Related: Conference reports.
World AIDS 16 Toronto 2006
Prevalence and predictors of squamous intraepithelial lesions of the cervix in HIV positive women in Lusaka, Zambia
7 October 2006. Related: Conference reports, Women's health, Cancer and HIV.
Effect of herpes simplex therapy on genital and plasma HIV viral load
7 October 2006. Related: Conference reports, Women's health.
Maternal health and prevention of mother to child transmission
7 October 2006. Related: Conference reports, Pregnancy.
18-month effectiveness of short-course perinatal antiretroviral regimens combined to infant-feeding interventions for PMTCT in DITRAME PLUS ANRS 1201/1202 2001-2005
7 October 2006. Related: Conference reports, Pregnancy.
HIV prevalence rates amongst 6 week old infants in South Africa: the case for universal screening at immunisation clinics
7 October 2006. Related: Conference reports, Pregnancy.
Maternal illness during pregnancy is associated with In utero mother to child transmission
7 October 2006. Related: Conference reports, Pregnancy.
Extensively drug resistant TB (XTB) in South Africa
7 October 2006. Related: Conference reports, TB coinfection.
XVI International AIDS Conference, Toronto, Canada. 13-18 August 2006
15 September 2006. Related: Conference reports.
Enough is enough: South African activists demand: fire Manto
10 September 2006. Related: Conference reports, Treatment access.
Treatment access: more optimistic results from scale up programmes
10 September 2006. Related: Conference reports, Treatment access.
Integrase inhibitor MK-0518: early results show greater early potency than efavirenz
10 September 2006. Related: Conference reports, Antiretrovirals.
Maraviroc results in R5/X4 mixed/dual tropic patients: unexpected safety data shows possible immunolocical effect
10 September 2006. Related: Conference reports, Antiretrovirals.
Vicriviroc 24-week results in triple-class experienced R5-tropic patients
10 September 2006. Related: Conference reports, Antiretrovirals.
Etravirine (TMC-125) associated with -1 log viral load reduction at 48-weeks results in treatment experienced patients
9 September 2006. Related: Conference reports, Antiretrovirals.
Three-class experienced patients experience 1 log viral load reduction using monoclonal antibody TNX-355
9 September 2006. Related: Conference reports, Antiretrovirals.
New data on darunavir (TMC-114)
9 September 2006. Related: Conference reports, Antiretrovirals.
Lopinavir/r monotherapy: less potent than triple therapy with higher risk of resistance
9 September 2006. Related: Conference reports, Antiretrovirals.
Atazanavir/r monotherapy and CNS penetration
9 September 2006. Related: Conference reports, Antiretrovirals.
Fosamprenavir/r is non-inferior to Kaletra in treatment naive patients
9 September 2006. Related: Conference reports, Antiretrovirals.
Tenofovir/FTC maintains greater virological response and reduced lipoatrophy compared to AZT/3TC after 96 weeks
9 September 2006. Related: Conference reports, Antiretrovirals.
Children face a serious service delivery gap: paediatric studies in Toronto
9 September 2006. Related: Conference reports, Paediatric care.
Bioavailability study results for new paediatric tablets for oral suspension, and caution against splitting adult doses
9 September 2006. Related: Conference reports, Paediatric care.
Pharmacokinetic and virological evaluations after stopping NNRTIs in children: a substudy of the PENTA 11 (TICCH) Trial
9 September 2006. Related: Conference reports, Paediatric care.
3TC/abacavir maintains virological superiority over AZT/3TC and AZT/abacavir beyond 5 years in children
9 September 2006. Related: Conference reports, Paediatric care.
French study raises importance of early screening for anal cancer in HIV-positive people
9 September 2006. Related: Conference reports, Coinfections and complications, Cancer and HIV.
Prognostic index for risk of progression of Kaposis Sarcoma
9 September 2006. Related: Conference reports, Coinfections and complications.
Tenofovir did not increase the incidence nephrotoxicity in limited numbers of HIV-positive patients using chemotherapy or HCV-coinfeced patients using ribavirin
9 September 2006. Related: Conference reports, Side effects, Cancer and HIV.
Selected abstracts from Track A presentations at Toronto
9 September 2006. Related: Conference reports, Basic science and immunology.
Use of complementary alternative medicine that could interact with ARV treatment reported by 20% patients in the UK
9 September 2006. Related: Conference reports.
Poor scientific or medical knowledge is a factor in increase in criminal charges for HIV transmission in the UK
9 September 2006. Related: Conference reports.
Treatment access and community responses: online webcasts and debates
9 September 2006. Related: Conference reports, Treatment access.